Abivax SA (ABVX) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed Abivax SA (ABVX) over the past year, gaining 404.7% versus a gain of 0.0%. Abivax SA is the larger company by market cap ($7.77 billion vs $7.37 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVX | SYRE |
|---|---|---|
| Share price | $89.05 | $79.90 |
| Market cap | $7.77B | $7.37B |
| 1-day change | +2.34% | -1.18% |
| YTD return | -35.48% | +146.79% |
| 1-year return | 0.00% | +404.68% |
| 5-year return | — | -60.46% |
| EPS (TTM) | $-6.08 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | — | $-155.20M |
| 52-week high | $148.83 | $110.18 |
| 52-week low | $69.81 | $17.65 |
| Distance from 52-week high | -40.17% | -27.48% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +84.17% | +50.45% |
| Average volume | 1.10M | 1.20M |
| Shares outstanding | 87.27M | 92.29M |
| Employees | 98 | 125 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SYRE has outperformed ABVX by 404.7 percentage points over the past year.
About Abivax SA
ABVX stock →ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Health Care · Biotechnology: Pharmaceutical Preparations · 125 employees
ABVX vs SYRE FAQ
Which is bigger, Abivax SA or Spyre Therapeutics?
Abivax SA (ABVX) is larger, with a market capitalization of $7.77B compared with $7.37B for Spyre Therapeutics (SYRE).
Which stock has performed better over the past year, ABVX or SYRE?
SYRE returned +404.68% over the past 12 months, compared with 0.00% for ABVX (price return, excluding dividends). Past performance does not predict future results.
Are Abivax SA and Spyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.